Blade Therapeutics
442 Littlefield Avenue
South San Francisco
California
94080
United States
Tel: 650-278-4291
Website: http://www.blademed.com/
About Blade Therapeutics
Blade Therapeutics is a private biopharmaceutical company revolutionizing the treatment of fibrotic disease. Blade’s novel target biology was discovered by its founder, Hal Dietz, M.D., Victor A. McKusick Professor of Genetics and Medicine, Johns Hopkins University. Blade licensed intellectual property associated with Dr. Dietz’s work and is advancing new compounds to halt the progression of fibrotic disease. Fibrosis, a pathologic process in which progressive scarring replaces functional tissue, drives the progression of several debilitating diseases. By targeting novel pathways common to multiple fibrotic disease states, we believe we can build the leading company in anti-fibrotic drug discovery and development.
YEAR FOUNDED:
2015
LEADERSHIP:
CEO: Wendye Robbins, M.D.
JOBS:
Please click here for Blade Therapeutics job opportunities.
43 articles about Blade Therapeutics
-
Blade Therapeutics Presents Analyses from Phase 1 and Preclinical Studies of Cudetaxestat at the European Respiratory Society International Congress 2022
9/4/2022
Blade Therapeutics, Inc., a clinical-stage biopharmaceutical company developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, announced the presentation of positive data from Phase 1 and preclinical studies of cudetaxestat, an investigational non-competitive autotaxin inhibitor in clinical development for IPF and other fibrotic diseases.
-
Blade Therapeutics to Participate in “Drug Development in Pulmonary Medicine” Panel Discussion at 2022 BTIG Biotechnology Conference
8/1/2022
Blade Therapeutics, Inc., a clinical-stage biopharmaceutical company developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced that Wendye Robbins, M.D., president and CEO, will participate in the “Drug Development in Pulmonary Medicine: Emerging Trends and a Review of the Unmet Need” panel discussion on Tuesday, August 9, 2022, 1:00 pm (ET).
-
Biotech Acquisition Company and Blade Therapeutics Mutually Agree to Terminate Business Combination Agreement
6/13/2022
Biotech Acquisition Company (NASDAQ: BIOT) ("BAC"), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, and Blade Therapeutics, Inc. ("Blade"), a biopharmaceutical company based in South San Francisco, Calif., today announced that they have mutually agreed to terminate the previously announced Agreement and Plan of Merger (the "Merger Agreement"), effective immediately.
-
Biotech Acquisition Company and Blade Therapeutics Announce Postponement of Extraordinary Meeting of Shareholders to Approve Proposed Business Combination
5/31/2022
Extraordinary General Meeting of BAC's shareholders postponed until June 3, 2022 , at 10:00 a.m., Eastern Time.
-
Closing out the month of May, plenty of companies presented or announced clinical trial updates and news. Here’s a look.
-
Blade Therapeutics Presents Preclinical Data Highlighting Differentiating Characteristics of Cudetaxestat at the American Thoracic Society 2022 International Conference
5/18/2022
Blade Therapeutics, Inc., a biopharmaceutical company focused on developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced new data from preclinical studies that highlight the differentiating characteristics of cudetaxestat, an investigational non-competitive autotaxin inhibitor in clinical development for IPF and other fibrotic diseases.
-
Blade Therapeutics Presents Data from Phase 1 and Preclinical Studies of Cudetaxestat at the American Thoracic Society 2022 International Conference
5/16/2022
Blade Therapeutics, Inc., a biopharmaceutical company focused on developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced encouraging data from phase 1 and preclinical DDI studies of cudetaxestat, an investigational non-competitive autotaxin inhibitor in clinical development for IPF and other fibrotic diseases.
-
Blade Therapeutics Announces Feedback from FDA on End-of-Phase 1 Data Package
4/4/2022
Blade Therapeutics, Inc. today announced receipt of feedback from the FDA regarding the company’s end-of-phase 1 data package for cudetaxestat, an investigational non-competitive autotaxin inhibitor in clinical development for treatment of IPF and other fibrotic diseases.
-
Blade Therapeutics to Present Data from Preclinical and Phase 1 Studies of Cudetaxestat at the American Thoracic Society 2022 International Conference
3/24/2022
Blade Therapeutics, Inc. today announced that the company will present data for cudetaxestat in three posters at the American Thoracic Society (ATS) 2022 International Conference, May 13-18, 2022, The Moscone Center, in San Francisco.
-
Blade Therapeutics to Participate in Upcoming Investor Conferences - Mar 07, 2022
3/7/2022
Blade Therapeutics, Inc. announced that Wendye Robbins, M.D., president and CEO, will present at two investor conferences in March.
-
Clinical Catch-Up: January 10-14
1/17/2022
Heading into the middle of January, companies announced plenty of new clinical trial news. Here’s a look. -
Blade Therapeutics Announces Successful Completion of Phase 1 Clinical Study that Evaluated Co-Administration of Cudetaxestat with Either of Two Approved Therapies for Idiopathic Pulmonary Fibrosis
1/12/2022
Blade Therapeutics, Inc. today announced the successful completion of a phase 1 drug-drug interaction clinical study of cudetaxestat, an investigational non-competitive autotaxin inhibitor in clinical development for IPF and other fibrotic diseases.
-
Going through the most newsworthy stories of the year, BioSpace found trends more than one big story, topics that just kept rising again and again. Here’s a look.
-
Heading out of November and into December, plenty of companies had clinical trial news to report. Here’s a look.
-
Blade Therapeutics Announces Positive Topline Data from Phase 1 Clinical Study of Cudetaxestat, a Non-Competitive Autotaxin Inhibitor in Clinical Development for Idiopathic Pulmonary Fibrosis
11/30/2021
Blade Therapeutics, Inc. today announced positive topline data from a phase 1 drug-drug interaction clinical study of cudetaxestat, an investigational non-competitive autotaxin inhibitor in clinical development for IPF.
-
Blade Therapeutics Appoints Bassem Elmankabadi, M.D., as Senior Vice President of Clinical Development
11/18/2021
Blade Therapeutics, Inc. today announced the appointment of Bassem Elmankabadi, M.D., as senior vice president of clinical development.
-
The merger between Blade Therapeutics and Biotech Acquisition Company will provide the company with $254.3 million to drive the development of cudetaxestat.
-
Clinical Catch-Up: October 18-22
10/25/2021
It was yet another busy week for clinical trial news. Here’s a look. -
Blade Therapeutics Initiates Additional Phase 1 Clinical Study of Cudetaxestat, a Non-Competitive Autotaxin Inhibitor in Clinical Development for Idiopathic Pulmonary Fibrosis
10/18/2021
Blade Therapeutics, Inc. (Blade or the company), a biopharmaceutical company focused on developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced the initiation of a phase 1 drug-drug interaction clinical study of cudetaxestat.
-
Blade Therapeutics Announces FDA Orphan Drug Designation Granted to Cudetaxestat for Treatment of Systemic Sclerosis
10/14/2021
Blade Therapeutics, Inc. today announced that the FDA has granted orphan drug designation for cudetaxestat for the potential treatment of systemic sclerosis (SSc). Cudetaxestat is an investigational non-competitive autotaxin inhibitor in clinical development for IPF.